Efficacy of tiapride in the maintenance of abstinence in weaned alcoholics. Results of a double blind trial against placebo
DOI:
https://doi.org/10.20882/adicciones.487Keywords:
Alcoholism, treatment, tiaprideAbstract
Introduction: Tiapride has been proposed as an adjunct in pharmacological treatment in the postweaning phase of alcoholism treatment, as well as in the detoxification period. This trial attempts to test its efficacy in a sample of alcoholics in Spain. Material and method: 81 detoxified alcoholics from 4 different centres and with a clinical diagnosis of alcohol dependence (DSM III-R), were randomly allocated to the experimental (tiapride, n= 38) and control (placebo, n= 43) groups. All patients were given tiapride 100 mg (or matching placebo tablets), to be taken every 8 hours for 24 weeks. 11 controls were scheduled and blood samples were collected on weeks 8, 16 and 24. Statistical analysis was performed under the ITT principle, and Time to first Relapse (TFR) and Cumulated Abstinence Duration (CAD) were used as the main outcome measures. Results: No significant differences were found between both samples in terms of sociodemographic variables, clinical characteristics of alcohol dependence and biological markers of alcoholism. Attrition rates were slightly higher in the placebo group (18% versus 35%) without reaching statistical significance (p.09). At the 6 months follow up, 49% patients in the placebo group and 37% in the tiapride group were still abstinent, with a mean TFR of 97 versus 88 days in favour of the placebo group (p.27). CAD values were also similar for both groups (130 versus 138 days in favour of tiapride; p.57). Conclusion: Our data do not support the hypothesis that tiapride can enhance abstinence rates in weaned alcoholics.References
(1) Sass H, Soyka M, Mann K, Zieglgansberger W Relapse prevention by acamprosate. Results from a placebocontrolled
study on alcohol dependence. Arch Gen Psychiatry (United States), 1996; 53(8):673-80.
(2) Poldrugo F Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction (England) 1997; 92(11):1537-46.
(3) O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry (United States), 1992; 49(11):881-7.
(4) Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP Naltrexone in the treatment of alcohol dependence Arch Gen Psychiatry (United States), 1992; 49(11):876-80.
(5) Pettinati, H. Placebo-controlled trial of sertraline for primary alcohol dependence. Alcohol Alcohol (England), 1999; 34(3): 432.
(6) Angelone SM, Bellini L, Di Bella D, Catalano M Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics. Alcohol Alcohol (England), 1998; 33(2):151-6.
(7) Naranjo CA, Dongier M, Bremner KE Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction (England), 1997; 92(8):969-78.
(8) Boening J, Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Flupenthixol decanoate for relapse prevention in alcohol dependence. Results from an international, double blind multicenter trial. Alcohol Alcohol (England), 1999; 34(3): 455.
(9) Moncrieff J, Drummond DC New drug treatments for alcohol problems: a critical appraisal. Addiction (England), 1997; 92(8):939-47.
(10) Gual, A. Editorial. Alcoscope (England), 1998; Vol 1(3): 1.
(11) Peters DH, Faulds D. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs (New Zealand), 1994; 47(6):1010-32.
(12) Soyka, M. Relapse prevention in alcoholism. Recent advances and future possibilities. CNS Drugs (New Zealand), 1997; 7(4): 313-327.
(13) Lepola U, Kokko S, Nuutila J, Gordin A. Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial. Int J Clin Pharmacol Res (Switzerland), 1984; 5:321-326.
(14) Murphy DJ, Shaw GK, Clarke I. Tiapride and chlormethiazole in alcohol withdrawal: a double blind trial. Alcohol Alcohol (England), 1983; 18: 227-237.
(15) Delamaire D, Carpentier MC, Eudier F, Derouet J, Bourel M Essai ambulatoire du tiapridal aprés sevrage alcoholique hospitalier. Semaine des Hôpitaux de Paris 1986; 62: 3109-3114.
(16) Shaw GK, Majumdar SK, Waller S, MacGarvie J, Dunn G Tiapride in the long term management of alcoholics of anxious or depressive temperament. Br J Psychiatry (England), 1987; 150,: 164-168.
(17) Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry (England), 1994; 165(4):515-23.
(18) Lehert P Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol (England), 1993; Suppl 2:157-163.
